Table 1.
Immune risk profiles comparison before and after hyperthermic intraperitoneal chemotherapy and immunotherapy
| Before (HIPEC) and immunotherapy | 1 week after (HIPEC) and immunotherapy | 3 months after (HIPEC) and immunotherapy | |
|---|---|---|---|
| T-CD3 | 67.4 | 76.7 | 79.2 |
| B-CD19 | 16.9 | 6.5 | 7.0 |
| CD25 | 7.6 | 3.6 | 2.7 |
| CD4+CD25+ | 5.8 | 3.1 | 2.6 |
| HLA-DR+ | 62.2 | 54.5 | 42.2 |
| CD3+DR+ | 33.8 | 41 | 32.2 |
| CD11b+ | 22.3 | 19.3 | 24.8 |
| CD8+CD11b+ | 5.1 | 5.4 | 7.3 |
| CD4 T cell | 28.9 | 33.3 | 40 |
| CD8 T cell | 31.6 | 40.3 | 37.7 |
| CD4/CD8 | 0.9 | 0.8 | 1.1 |
| NK-cell | 12.8 | 18.2 | 15.7 |
| CD28 | 34.9 | 32.2 | 37.9 |
| NKT | 3.4 | 6.0 | 7.2 |
| CD3+CD279+ | 6.3 | 0.5 | 0.4 |
| CD154+ | 5.0 | 0.5 | 0.6 |
| CD152 | - | - | <0.1 |
HIPEC: Hyperthermic intraperitoneal chemotherapy, NKT: Natural killer T cell